Targeting CLL-1 for acute myeloid leukemia therapy

Autor: Iyer Swaminathan Padmanabhan, Hongbing Ma, Yuping Gong, Simrit Parmar
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Cancer Research
medicine.medical_specialty
medicine.medical_treatment
CD33
Review
lcsh:RC254-282
hMICL
03 medical and health sciences
Mice
0302 clinical medicine
immune system diseases
Internal medicine
Cell Line
Tumor
hemic and lymphatic diseases
medicine
Animals
Humans
Lectins
C-Type
Molecular Biology
neoplasms
CD371
CD70
CLEC12A
Hematology
Acute myeloid leukemia
business.industry
lcsh:RC633-647.5
Myeloid leukemia
Hematopoietic stem cell
Immunotherapy
lcsh:Diseases of the blood and blood-forming organs
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Leukemia
Lymphocytic
Chronic
B-Cell
Disease Models
Animal
030104 developmental biology
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
Receptors
Mitogen
Cancer research
DCAL-2
Chimeric Antigen Receptor T-Cell Therapy
Interleukin-3 receptor
business
CLL-1
Zdroj: Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-11 (2019)
Journal of Hematology & Oncology
ISSN: 1756-8722
Popis: Despite major scientific discoveries and novel therapies over the past four decades, the treatment outcomes of acute myeloid leukemia (AML), especially in the adult patient population remain dismal. In the past few years, an increasing number of targets such as CD33, CD123, CLL-1, CD47, CD70, and TIM3, have been developed for immunotherapy of AML. Among them, CLL-1 has attracted the researchers’ attention due to its high expression in AML while being absent in normal hematopoietic stem cell. Accumulating evidence have demonstrated CLL-1 is an ideal target for AML. In this paper, we will review the expression of CLL-1 on normal cells and AML, the value of CLL-1 in diagnosis and follow-up, and targeting CLL-1 therapy-based antibody and chimeric antigen receptor T cell therapy as well as providing an overview of CLL-1 as a target for AML.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje